A study testing whether a new weekly shot from University of Southern California, tirzepatide, works for this condition.
- Who can join
- Adults 21 to 65, have smoking cessation, BMI 25+.
- What you take
- tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.3 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Smoking Cessation. Also studied in: Smoking Behaviors.
Full scientific study title: Multi-Site Trial of Tirzepatide for Smoking Cessation.
Who can join
Adults 21 to 65, have smoking cessation, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 21-65 years
- Body mass index >= 25kg/m2 at the baseline screening
- Reporting >=10 cigarettes per day, on average, for the past 6 months and > 2 year duration of smoking
- Interest in making a long-term cessation attempt within the next 30-60 days
- Willingness to receive study medication and standard-of-care smoking cessation supports (nicotine replacement therapy and a smoking cessation app)
Key exclusion criteria
- BMI < 25 kg/m2 at screening
- History of diabetes, diabetes-attributable medical conditions, or HbA1c >=6.5% at baseline
- Recent (past 90 days) active suicidal ideation or lifetime history of suicide attempt
- Current treatment for psychotic disorders or mood disorders with psychotic features (e.g., schizophrenia, schizoaffective disorder, depression with psychotic features), current treatment for bipolar disorder (with or without psychotic features), or current secondary psychosis due to substance use or another medical condition
- Meeting DSM-5 criteria for a current (past 12 months) substance use disorder other than tobacco use disorder, mild or moderate cannabis use disorder, or mild or moderate alcohol use disorder.
Where this study is enrolling
This trial has 4 sites across 4 states. Contact a site coordinator directly to start screening.
California1 site
- Keck School of Medicine, University of Southern CaliforniaLos Angeles, California
Colorado1 site
- University of Colorado Anschutz Medical CampusAurora, Colorado303-724-3196kristen.raymond@cuanschutz.edu
Connecticut1 site
- Yale University School of MedicineNew Haven, Connecticut
Illinois1 site
- University of Chicago Pritzker School of MedicineChicago, Illinois
Timeline
Started enrolling: 2026-05-31. Expected completion: 2028-09. Last updated on ClinicalTrials.gov: 2026-05-22.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.